1
|
Murray D, How-Chow D, Barreto L, Smith M. P41 Advancing the development of community-based models to access marginalised populations for hepatitis C treatment incorporating assessment, outreach and case management. J Virus Erad 2017. [DOI: 10.1016/s2055-6640(20)30782-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
2
|
Marshall AD, Micallef M, Erratt A, Telenta J, Treloar C, Everingham H, Jones SC, Bath N, How-Chow D, Byrne J, Harvey P, Dunlop A, Jauncey M, Read P, Collie T, Dore GJ, Grebely J. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. Int J Drug Policy 2015; 26:984-91. [PMID: 26256938 DOI: 10.1016/j.drugpo.2015.07.002] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Revised: 06/19/2015] [Accepted: 07/07/2015] [Indexed: 02/07/2023]
Abstract
BACKGROUND The aim of this study was to assess factors associated with baseline knowledge of HCV and liver disease, acceptability of transient elastography (TE) assessment (FibroScan(®)), and willingness and intent to receive HCV treatment among persons with a history of injection drug use participating in a liver health promotion campaign. METHODS The LiveRLife campaign involved three phases: (1) campaign resource development; (2) campaign resource testing; and (3) campaign implementation. Participants were enrolled in an observational cohort study with recruitment at four clinics - one primary health care facility, two OST clinics, and one medically supervised injecting centre - in Australia between May and October 2014. Participants received educational material, nurse clinical assessment, TE assessment, dried blood spot testing, and completed a knowledge survey. RESULTS Of 253 participants (mean age 43 years), 68% were male, 71% had injected in the past month, and 75% self-reported as HCV positive. Median knowledge score was 16/23. In adjusted analysis, less than daily injection (AOR 5.01; 95% CI, 2.64-9.51) and no daily injection in the past month (AOR 3.54; 95% CI, 1.80-6.94) were associated with high knowledge (≥16). TE was the most preferred method both pre- (66%) and post-TE (89%) compared to liver biopsy and blood sample. Eighty-eight percent were 'definitely willing' or 'somewhat willing' to receive HCV treatment, and 56% intended to start treatment in the next 12 months. Approximately 68% had no/mild fibrosis (F0/F1, ≥2.5 to ≤7.4kPa), 13% moderate fibrosis (F2, ≥7.5 to ≤9.4kPa), 10% severe fibrosis (F3, ≥9.5 to ≤12.4kPa), and 9% had cirrhosis (F4, ≥12.5kPa). CONCLUSION Liver disease and HCV knowledge was moderate. High acceptability of TE by PWID provides strong evidence for the inclusion of TE in HCV-related care, and could help to prioritise HCV treatment for those at greatest risk of liver disease progression.
Collapse
Affiliation(s)
- A D Marshall
- The Kirby Institute, UNSW Australia, NSW, Australia.
| | - M Micallef
- The Kirby Institute, UNSW Australia, NSW, Australia
| | - A Erratt
- The Kirby Institute, UNSW Australia, NSW, Australia
| | - J Telenta
- Centre for Health and Social Research, Australian Catholic University, VIC, Australia
| | - C Treloar
- Centre for Social Research in Health, UNSW Australia, NSW, Australia
| | - H Everingham
- NSW Users and AIDS Association, Inc., NSW, Australia
| | - S C Jones
- Centre for Health and Social Research, Australian Catholic University, VIC, Australia
| | - N Bath
- NSW Users and AIDS Association, Inc., NSW, Australia
| | - D How-Chow
- St Vincent's Hospital Sydney, NSW, Australia
| | - J Byrne
- Australian Injecting and Illicit Drug Users League, ACT, Australia
| | | | - A Dunlop
- University of Newcastle, Newcastle, NSW, Australia; Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, NSW, Australia
| | - M Jauncey
- Australian Injecting and Illicit Drug Users League, ACT, Australia
| | - P Read
- The Kirby Institute, UNSW Australia, NSW, Australia; Kirketon Road Centre, NSW, Australia
| | - T Collie
- Coffs Harbour Drug and Alcohol Service, NSW, Australia
| | - G J Dore
- The Kirby Institute, UNSW Australia, NSW, Australia
| | - J Grebely
- The Kirby Institute, UNSW Australia, NSW, Australia
| |
Collapse
|